ABBV logo AbbVie +
AbbVie
+
Revenue breakdown by Products & Services
Revenue breakdown by Geography

AbbVie's Revenue by Segment

In fiscal year 2025, AbbVie's revenue by segment (products & services) are as follows:

  • Alphagan/Combigan: $197.00 M
  • Botox Cosmetic: $2.60 B
  • Botox Therapeutic: $3.77 B
  • Duodopa: $381.00 M
  • H U M I R A: $4.54 B
  • Imbruvica: $2.87 B
  • Juvederm Collection: $993.00 M
  • Linzess/Constella: $907.00 M
  • Lumigan/Ganfort: $410.00 M
  • MAVYRET: $1.32 B
  • Other Aesthetics: $1.27 B
  • Other Eye Care: $1.01 B
  • Other Neuroscience: $207.00 M
  • Other Products: $2.63 B
  • Ozurdex: $493.00 M
  • Qulipta: $1.04 B
  • RINVOQ: $8.30 B
  • SKYRIZI: $17.56 B
  • Ubrelvy: $1.27 B
  • VENCLEXTA: $2.79 B
  • Vraylar: $3.62 B

Learn more about AbbVie’s Revenue by Geography

Check out competitors to AbbVie in a side-by-side comparison.

Explore additional financial metrics for AbbVie.

Continue reading...

The above chart shows AbbVie's revenue percentage share by segment (products and services).

In fiscal year 2023, AbbVie's revenue by segment is as follows:

  • Alphagan/Combigan generated $272.00 M in revenue, representing 0.51% of its total revenue.
  • Botox Cosmetic generated $2.68 B in revenue, representing 5.06% of its total revenue.
  • Botox Therapeutic generated $2.99 B in revenue, representing 5.64% of its total revenue.
  • Duodopa generated $468.00 M in revenue, representing 0.88% of its total revenue.
  • H U M I R A generated $14.40 B in revenue, representing 27.17% of its total revenue.
  • Imbruvica generated $3.60 B in revenue, representing 6.78% of its total revenue.
  • Juvederm Collection generated $1.38 B in revenue, representing 2.6% of its total revenue.
  • Linzess/Constella generated $1.11 B in revenue, representing 2.09% of its total revenue.
  • Lumigan/Ganfort generated $432.00 M in revenue, representing 0.81% of its total revenue.
  • MAVYRET generated $1.43 B in revenue, representing 2.7% of its total revenue.
  • Other Aesthetics generated $1.23 B in revenue, representing 2.33% of its total revenue.
  • Other Eye Care generated $803.00 M in revenue, representing 1.51% of its total revenue.
  • Other Neuroscience generated $276.00 M in revenue, representing 0.52% of its total revenue.
  • Other Products generated $3.04 B in revenue, representing 5.72% of its total revenue.
  • Ozurdex generated $472.00 M in revenue, representing 0.89% of its total revenue.
  • Qulipta generated $408.00 M in revenue, representing 0.77% of its total revenue.
  • Restasis generated $436.00 M in revenue, representing 0.82% of its total revenue.
  • RINVOQ generated $3.97 B in revenue, representing 7.49% of its total revenue.
  • SKYRIZI generated $7.76 B in revenue, representing 14.64% of its total revenue.
  • Ubrelvy generated $815.00 M in revenue, representing 1.54% of its total revenue.
  • VENCLEXTA generated $2.29 B in revenue, representing 4.32% of its total revenue.
  • Vraylar generated $2.76 B in revenue, representing 5.2% of its total revenue.

The biggest segment for AbbVie is the H U M I R A, which represents 27.17% of its total revenue.
The smallest segment for AbbVie is the Alphagan/Combigan, which represents 0.51% of its total revenue.

The above chart shows AbbVie's revenue percentage share by segment (products and services).

In fiscal year 2024, AbbVie's revenue by segment is as follows:

  • Alphagan/Combigan generated $248.00 M in revenue, representing 0.46% of its total revenue.
  • Botox Cosmetic generated $2.72 B in revenue, representing 5.01% of its total revenue.
  • Botox Therapeutic generated $3.28 B in revenue, representing 6.04% of its total revenue.
  • Duodopa generated $447.00 M in revenue, representing 0.82% of its total revenue.
  • H U M I R A generated $8.99 B in revenue, representing 16.55% of its total revenue.
  • Imbruvica generated $3.35 B in revenue, representing 6.16% of its total revenue.
  • Juvederm Collection generated $1.18 B in revenue, representing 2.17% of its total revenue.
  • Linzess/Constella generated $954.00 M in revenue, representing 1.76% of its total revenue.
  • Lumigan/Ganfort generated $429.00 M in revenue, representing 0.79% of its total revenue.
  • MAVYRET generated $1.31 B in revenue, representing 2.41% of its total revenue.
  • Other Aesthetics generated $1.28 B in revenue, representing 2.35% of its total revenue.
  • Other Eye Care generated $847.00 M in revenue, representing 1.56% of its total revenue.
  • Other Neuroscience generated $338.00 M in revenue, representing 0.62% of its total revenue.
  • Other Products generated $3.03 B in revenue, representing 5.58% of its total revenue.
  • Ozurdex generated $494.00 M in revenue, representing 0.91% of its total revenue.
  • Qulipta generated $658.00 M in revenue, representing 1.21% of its total revenue.
  • Restasis generated $224.00 M in revenue, representing 0.41% of its total revenue.
  • RINVOQ generated $5.97 B in revenue, representing 10.99% of its total revenue.
  • SKYRIZI generated $11.72 B in revenue, representing 21.57% of its total revenue.
  • Ubrelvy generated $1.01 B in revenue, representing 1.85% of its total revenue.
  • VENCLEXTA generated $2.58 B in revenue, representing 4.75% of its total revenue.
  • Vraylar generated $3.27 B in revenue, representing 6.01% of its total revenue.

The biggest segment for AbbVie is the SKYRIZI, which represents 21.57% of its total revenue.
The smallest segment for AbbVie is the Restasis, which represents 0.41% of its total revenue.

The above chart shows AbbVie's revenue percentage share by segment (products and services).

In fiscal year 2025, AbbVie's revenue by segment is as follows:

  • Alphagan/Combigan generated $197.00 M in revenue, representing 0.34% of its total revenue.
  • Botox Cosmetic generated $2.60 B in revenue, representing 4.47% of its total revenue.
  • Botox Therapeutic generated $3.77 B in revenue, representing 6.48% of its total revenue.
  • Duodopa generated $381.00 M in revenue, representing 0.65% of its total revenue.
  • H U M I R A generated $4.54 B in revenue, representing 7.8% of its total revenue.
  • Imbruvica generated $2.87 B in revenue, representing 4.93% of its total revenue.
  • Juvederm Collection generated $993.00 M in revenue, representing 1.71% of its total revenue.
  • Linzess/Constella generated $907.00 M in revenue, representing 1.56% of its total revenue.
  • Lumigan/Ganfort generated $410.00 M in revenue, representing 0.7% of its total revenue.
  • MAVYRET generated $1.32 B in revenue, representing 2.26% of its total revenue.
  • Other Aesthetics generated $1.27 B in revenue, representing 2.17% of its total revenue.
  • Other Eye Care generated $1.01 B in revenue, representing 1.73% of its total revenue.
  • Other Neuroscience generated $207.00 M in revenue, representing 0.36% of its total revenue.
  • Other Products generated $2.63 B in revenue, representing 4.52% of its total revenue.
  • Ozurdex generated $493.00 M in revenue, representing 0.85% of its total revenue.
  • Qulipta generated $1.04 B in revenue, representing 1.78% of its total revenue.
  • RINVOQ generated $8.30 B in revenue, representing 14.27% of its total revenue.
  • SKYRIZI generated $17.56 B in revenue, representing 30.19% of its total revenue.
  • Ubrelvy generated $1.27 B in revenue, representing 2.18% of its total revenue.
  • VENCLEXTA generated $2.79 B in revenue, representing 4.8% of its total revenue.
  • Vraylar generated $3.62 B in revenue, representing 6.22% of its total revenue.

The biggest segment for AbbVie is the SKYRIZI, which represents 30.19% of its total revenue.
The smallest segment for AbbVie is the Alphagan/Combigan, which represents 0.34% of its total revenue.
Continue reading...

Summary Table

Products & Services (Percent Share) 2023 2024 2025
VENCLEXTA 4.32% 4.75% 4.8%
H U M I R A 27.17% 16.55% 7.8%
RINVOQ 7.49% 10.99% 14.27%
SKYRIZI 14.64% 21.57% 30.19%
Botox Therapeutic 5.64% 6.04% 6.48%
Duodopa 0.88% 0.82% 0.65%
Other Neuroscience 0.52% 0.62% 0.36%
Qulipta 0.77% 1.21% 1.78%
Ubrelvy 1.54% 1.85% 2.18%
Vraylar 5.2% 6.01% 6.22%
Linzess/Constella 2.09% 1.76% 1.56%
Imbruvica 6.78% 6.16% 4.93%
Restasis 0.82% 0.41% -
Ozurdex 0.89% 0.91% 0.85%
Other Eye Care 1.51% 1.56% 1.73%
Lumigan/Ganfort 0.81% 0.79% 0.7%
Alphagan/Combigan 0.51% 0.46% 0.34%
Other Aesthetics 2.33% 2.35% 2.17%
Juvederm Collection 2.6% 2.17% 1.71%
Botox Cosmetic 5.06% 5.01% 4.47%
MAVYRET 2.7% 2.41% 2.26%
Other Products 5.72% 5.58% 4.52%
Total Revenue 100% 100% 100%

The above chart shows the revenue trend of different segments of AbbVie.

In fiscal year 2025, the SKYRIZI generated the most revenue ($17.56 B), and the Alphagan/Combigan generated the least revenue ($197.00 M).

The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Alphagan/Combigan revenue decreased -20.56% ($51.00 M) from $248.00 M (in 2024) to $197.00 M (in 2025).
  • Botox Cosmetic revenue decreased -4.34% ($118.00 M) from $2.72 B (in 2024) to $2.60 B (in 2025).
  • Botox Therapeutic revenue increased 14.8% ($486.00 M) from $3.28 B (in 2024) to $3.77 B (in 2025).
  • Duodopa revenue decreased -14.77% ($66.00 M) from $447.00 M (in 2024) to $381.00 M (in 2025).
  • H U M I R A revenue decreased -49.52% ($4.45 B) from $8.99 B (in 2024) to $4.54 B (in 2025).
  • Imbruvica revenue decreased -14.28% ($478.00 M) from $3.35 B (in 2024) to $2.87 B (in 2025).
  • Juvederm Collection revenue decreased -15.63% ($184.00 M) from $1.18 B (in 2024) to $993.00 M (in 2025).
  • Linzess/Constella revenue decreased -4.93% ($47.00 M) from $954.00 M (in 2024) to $907.00 M (in 2025).
  • Lumigan/Ganfort revenue decreased -4.43% ($19.00 M) from $429.00 M (in 2024) to $410.00 M (in 2025).
  • MAVYRET revenue increased 0.46% ($6.00 M) from $1.31 B (in 2024) to $1.32 B (in 2025).
  • Other Aesthetics revenue decreased -1.09% ($14.00 M) from $1.28 B (in 2024) to $1.27 B (in 2025).
  • Other Eye Care revenue increased 19.13% ($162.00 M) from $847.00 M (in 2024) to $1.01 B (in 2025).
  • Other Neuroscience revenue decreased -38.76% ($131.00 M) from $338.00 M (in 2024) to $207.00 M (in 2025).
  • Other Products revenue decreased -13.36% ($405.00 M) from $3.03 B (in 2024) to $2.63 B (in 2025).
  • Ozurdex revenue decreased -0.2% ($1,000.00) from $494.00 M (in 2024) to $493.00 M (in 2025).
  • Qulipta revenue increased 57.45% ($378.00 M) from $658.00 M (in 2024) to $1.04 B (in 2025).
  • Restasis revenue decreased -100% ($224.00 M) from $224.00 M (in 2024) to $0.00 (in 2025).
  • RINVOQ revenue increased 39.07% ($2.33 B) from $5.97 B (in 2024) to $8.30 B (in 2025).
  • SKYRIZI revenue increased 49.87% ($5.84 B) from $11.72 B (in 2024) to $17.56 B (in 2025).
  • Ubrelvy revenue increased 26.34% ($265.00 M) from $1.01 B (in 2024) to $1.27 B (in 2025).
  • VENCLEXTA revenue increased 8.09% ($209.00 M) from $2.58 B (in 2024) to $2.79 B (in 2025).
  • Vraylar revenue increased 10.84% ($354.00 M) from $3.27 B (in 2024) to $3.62 B (in 2025).
    • Continue reading...

    Summary Table

    Products & Services 2023
    Value Change
    		2024
    Value Change
    		2025
    Value Change
    Alphagan/Combigan $272.00 M - $248.00 M
    8.82%
    		$197.00 M
    20.56%
    Botox Cosmetic $2.68 B - $2.72 B
    1.42%
    		$2.60 B
    4.34%
    Botox Therapeutic $2.99 B - $3.28 B
    9.76%
    		$3.77 B
    14.80%
    Duodopa $468.00 M - $447.00 M
    4.49%
    		$381.00 M
    14.77%
    H U M I R A $14.40 B - $8.99 B
    37.57%
    		$4.54 B
    49.52%
    Imbruvica $3.60 B - $3.35 B
    6.92%
    		$2.87 B
    14.28%
    Juvederm Collection $1.38 B - $1.18 B
    14.59%
    		$993.00 M
    15.63%
    Linzess/Constella $1.11 B - $954.00 M
    13.90%
    		$907.00 M
    4.93%
    Lumigan/Ganfort $432.00 M - $429.00 M
    0.69%
    		$410.00 M
    4.43%
    MAVYRET $1.43 B - $1.31 B
    8.32%
    		$1.32 B
    0.46%
    Other Aesthetics $1.23 B - $1.28 B
    3.65%
    		$1.27 B
    1.09%
    Other Eye Care $803.00 M - $847.00 M
    5.48%
    		$1.01 B
    19.13%
    Other Neuroscience $276.00 M - $338.00 M
    22.46%
    		$207.00 M
    38.76%
    Other Products $3.04 B - $3.03 B
    0.10%
    		$2.63 B
    13.36%
    Ozurdex $472.00 M - $494.00 M
    4.66%
    		$493.00 M
    0.20%
    Qulipta $408.00 M - $658.00 M
    61.27%
    		$1.04 B
    57.45%
    Restasis $436.00 M - $224.00 M
    48.62%
    		- -
    RINVOQ $3.97 B - $5.97 B
    50.44%
    		$8.30 B
    39.07%
    SKYRIZI $7.76 B - $11.72 B
    50.95%
    		$17.56 B
    49.87%
    Ubrelvy $815.00 M - $1.01 B
    23.44%
    		$1.27 B
    26.34%
    VENCLEXTA $2.29 B - $2.58 B
    12.89%
    		$2.79 B
    8.09%
    Vraylar $2.76 B - $3.27 B
    18.41%
    		$3.62 B
    10.84%
    Total Revenue $53.02 B - $54.33 B
    2.47%
    		$58.17 B
    7.08%

    Frequently Asked Questions

    What was AbbVie's largest product segment last year?

    In fiscal year 2025, SKYRIZI revenue reached $17.56 Billion, representing 30.19% of AbbVie's total revenue and making it the largest segment for the company.

    Which product segment experienced the highest growth for AbbVie last year?

    The Qulipta segment is AbbVie's highest growth segment, with a revenue growth of +57.45% in 2025 compared to 2024.

    Related company

    Revenue Ranking

    Revenue Ranking

    Related

    Submit feedback to Bullfincher